• Echo IQ (ASX:EIQ) has locked in firm commitments for a ~A$110 million institutional placement at A$1.45 per share, representing an 8.8% discount to its last close.
  • The capital raise, covered by existing holders and new specialist healthcare funds, is intended to fund the US salesforce for its FDA-cleared EchoSolv AS product.
  • This announcement contradicts the original news's claim of no fresh company announcements explaining the decline, as the placement price is below current trading, providing a clear catalyst for the stock's movement.